ArticleJournal of the American Geriatrics Society2024
New statin use, mortality, and first cardiovascular events in older US Veterans by frailty status.
Article in Journal of the American Geriatrics Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- A Novel Approach to Manage Hypercholesterolemia: Veterans Affairs Lipid Optimization Reimagined Quality Improvement Program.JACC. Advances · 2026Article
- Statins and survival free of incident frailty among older US veterans.European heart journal · 2026Article
- Frailty and Cardiovascular Risk.European cardiology · 2026Review
- Development and validation of a deprescribing tool relevant to older persons in India using modified Delphi consensus technique.BMC geriatrics · 2025Article
- Frailty, Pitavastatin, and Major Adverse Cardiovascular Events Among People With HIV.JACC. Advances · 2025Article
- Managing Hypercholesterolemia in Adults Older Than 75 years Without a History of Atherosclerotic Cardiovascular Disease: An Expert Clinical Consensus From the National Lipid Association and the American Geriatrics Society.Journal of the American Geriatrics Society · 2025Article
- Association of the atherogenic index of plasma with frailty in U.S. adults: a cross-sectional study based on NHANES.Lipids in health and disease · 2025Article
- Unleashing frailty from laboratory into real world: A critical step toward frailty-guided clinical care of older adults.Journal of the American Geriatrics Society · 2024Article
- Treating Hypercholesterolemia in Older Adults for Primary Prevention of Cardiovascular Events.Drugs & aging · 2024Review
- Frailty and Cardiovascular Health.Journal of the American Heart Association · 2024Review
- Assessing the Benefits and Harms of Pharmacotherapy in Older Adults with Frailty: Insights from Pharmacoepidemiologic Studies of Routine Health Care Data.Drugs & aging · 2024Review
- The role of statin therapy in older adults: best practices and unmet challenges.Expert review of cardiovascular therapy · 2024Review
- Awaiting the verdict: Statins and the road ahead for primary prevention in older adults.Journal of the American Geriatrics Society · 2024Article
Corrections and comments
- Commented on by
Authors and funding
13 authors.
Funding
Abstract
backgroundStatins are part of long-term medical regimens for many older adults. Whether frailty modifies the protective relationship between statins, mortality, and major adverse cardiovascular events (MACE) is unknown.
methodsThis was a retrospective study of US Veterans ≥65, without CVD or prior statin use seen in 2002-2012, followed through 2017. A 31-item frailty index was used. The co-primary endpoint was all-cause mortality or MACE (MI, stroke/TIA, revascularization, or cardiovascular death). Cox proportional hazards models were developed to evaluate the association of statin use with outcomes; propensity score overlap weighting accounted for confounding by indication.
resultsWe identified 710,313 Veterans (mean age (SD) 75.3(6.5), 98% male, 89% white); 86,327 (12.1%) were frail. Over mean follow-up of 8 (5) years, there were 48.6 and 72.6 deaths per 1000 person-years (PY) among non-frail statin-users vs nonusers (weighted Incidence Rate Difference (wIRD)/1000 person years (PY), -24.0[95% CI, -24.5 to -23.6]), and 90.4 and 130.4 deaths per 1000PY among frail statin-users vs nonusers (wIRD/1000PY, -40.0[95% CI, -41.8 to -38.2]). There were 51.7 and 60.8 MACE per 1000PY among non-frail statin-users vs nonusers (wIRD/1000PY, -9.1[95% CI, -9.7 to -8.5]), and 88.2 and 102.0 MACE per 1000PY among frail statin-users vs nonusers (wIRD/1000PY, -13.8[95% CI, -16.2 to -11.4]). There were no significant interactions by frailty for statin users vs non-users by either mortality or MACE outcomes, p-interaction 0.770 and 0.319, respectively. Statin use was associated with lower risk of all-cause mortality (HR, 0.61 (0.60-0.61)) and MACE (HR 0.86 (0.85-0.87)).
conclusionsNew statin use is associated with a lower risk of mortality and MACE, independent of frailty. These findings should be confirmed in a randomized clinical trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.